CBL anticorps (AA 470-766)

N° du produit ABIN7601820

Cet anticorps Lapin Polyclonal détecte spécifiquement CBL dans WB, ELISA, IHC et FACS. Il présente une réactivité envers Humain, Souris et Rat.

Aperçu rapide pour CBL anticorps (AA 470-766) (ABIN7601820)

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CBL est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Détail du produit anti-CBL anticorps

Épitope: AA 470-766

Fonction: Anti-CBL Antibody Picoband®

Réactivité croisée (Details): No cross-reactivity with other proteins.

Attributs du produit: Anti-CBL Antibody Picoband® (ABIN7601820). Tested in ELISA, Flow Cytometry, IHC, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogène: E.coli-derived human CBL recombinant protein (Position: M470-E766).

Isotype: IgG

Information d'application

Indications d'application: Western blot, 0.25-0.5 μg/mL, Human, Mouse, Rat
Immunohistochemistry(Paraffin-embedded Section), 2-5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human
ELISA, 0.1-0.5 μg/mL, -
1. Joazeiro, C. A. P., Wing, S. S., Huang, H., Leverson, J. D., Hunter, T., Liu, Y.-C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286: 309-312, 1999. 2. Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., Ferrara, G., Digilio, M. C., and 14 others.Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am. J. Hum. Genet. 87: 250-257, 2010. 3. Wei, S., Rocchi, M., Archidiacono, N., Sacchi, N., Romeo, G., Gatti, R. A. Physical mapping of the human chromosome 11q23 region containing the ataxia-telangiectasia locus. Cancer Genet. Cytogenet. 46: 1-8, 1990.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Stock: 4 °C,-20 °C

Stockage commentaire: At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.

Détails sur CBL

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Autre désignation: CBL

Sujet:

Synonyms: Angiogenin,3.1.27.-,Ribonuclease 5,RNase 5,ANG,RNASE5,

Tissue Specificity: Expressed predominantly in the liver. Also detected in endothelial cells and spinal cord neurons. .

Background: CBL(Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes(E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Poids moléculaire: 120 kDa

ID gène: 867

UniProt: P22681

Pathways: TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals